Interviewed by Sisterhood editorial board member Sheila Gujrathi, Yvonne Greenstreet describes her upbringing and early career as a...

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for...

Yvonne Greenstreet shares her thoughts on key points of today's top-line, but as monotherapy and in combination, the potential market, and w

Yvonne Greenstreet talks about how Alnylam has been moving RNAi beyond the liver and previews the year ahead, including HELIOS-B.